Article thumbnail

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer

By Howard Burris, Joe Stephenson, Gregory A. Otterson, Mark Stein, Jesse McGreivy, Yu-Nien Sun, Megan Ingram, Yining Ye and Lee S. Schwartzberg


Purpose. The aim of this study was to assess the safety and tolerability of motesanib (an orally administered small-molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and Kit) when administered in combination with panitumumab, gemcitabine, and cisplatin. Methods. This was an open-label, multicenter phase 1b study in patients with advanced solid tumors with an ECOG performance status ≤1 and for whom a gemcitabine/cisplatin regimen was indicated. Patients received motesanib (0 mg [control], 50 mg once daily [QD], 75 mg QD, 100 mg QD, 125 mg QD, or 75 mg twice daily [BID]) with panitumumab (9 mg/kg), gemcitabine (1250 mg/m2) and cisplatin (75 mg/m2) in 21-day cycles. The primary endpoint was the incidence of dose-limiting toxicities (DLTs). Results. Forty-one patients were enrolled and received treatment (including 8 control patients). One of eight patients in the 50 mg QD cohort and 5/11 patients in the 125 mg QD cohort experienced DLTs. The maximum tolerated dose was established as 100 mg QD. Among patients who received motesanib (n = 33), 29 had motesanib-related adverse events. Fourteen patients had serious motesanib-related events. Ten patients had motesanib-related venous thromboembolic events and three had motesanib-related arterial thromboembolic events, two of which were considered serious. One patient had a complete response and nine had partial responses as their best objective response. Conclusions. The combination of motesanib, panitumumab, and gemcitabine/cisplatin could not be administered consistently and, at the described doses and schedule, may be intolerable. However, encouraging antitumor activity was noted in some cases

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). A b o u - A l f a ,L .S c h w a r t z ,S .R i c c ie ta l . ,“ P h a s eI I study of sorafenib in patients with advanced hepatocellular carcinoma,”
  2. (2008). A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity,”
  3. (2009). A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer,”
  4. (2006). AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts,”
  5. (2008). An open-label, single-armstudyassessingsafetyandefficacyofpanitumumab in patients with metastatic colorectal cancer refractory to standardchemotherapy,”AnnalsofOncology,v ol.19,no .1,pp .
  6. (2005). Angiogenesis in life, disease and medicine,”
  7. Cats et al., “Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer,”
  8. (2006). Cellular pharmacology of gemcitabine,”
  9. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial,”
  10. (2006). D e m e t r i ,A .T .v a nO o s t e r o m ,C .R .G a r r e t te ta l . , “Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial,”
  11. (2002). Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors,”
  12. (2003). e r r a r a ,H .P .G e r b e r ,a n dJ .L e C o u t e r ,“ T h eb i o l o g yo f VEGF and its receptors,” Nature Medicine,v o l .9 ,n o .6 ,p p .
  13. (2007). efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors,”
  14. (2006). Elimination mechanisms of therapeutic monoclonal antibodies,”
  15. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase
  16. (2002). H e i n r i c h ,C .D .B l a n k e ,B .J .D r u k e r ,a n dC .L .C o r l e s s , “Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies,”
  17. (2004). H.Hurwitz,L.Fehrenbacher,W.Novotnyetal.,“Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England
  18. Horsfield et al., “Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamicsofPTK787/ZK222584administeredtwice daily in patients with advanced cancer,”
  19. (2009). In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and
  20. (2008). Motesanib diphosphate in progressive differentiated thyroid cancer,”
  21. (2000). New guidelines to evaluate the response to treatment in solid tumors,”
  22. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,”
  23. (2007). Panitumumab with irinotecan/leucovorin/5-fluorouracilforfirst-linetreatmentof metastatic colorectal cancer,”
  24. (1996). Pharmacokineticsofcisplatinanditsmonohydratedcomplex in humans,”
  25. (2008). Phase 1b study of motesanib diphosphate (AMG 706) in combination with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer,”
  26. (2010). Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer,”
  27. (2005). Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results,”
  28. (2007). Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapyforpatientswithmetastasticcolorectalcancer,”
  29. (2009). Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer,”
  30. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patientswithadvancedpancreaticadenocarcinoma:southwest oncology group-directed intergroup trial S0205,”
  31. (2003). Platelet-derived growth factor signaling and human cancer,”
  32. (2005). Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine,”
  33. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer,”
  34. (2010). Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): patient-reported outcomes (PRO),”
  35. (2002). Role of angiogenesis in tumor growth and metastasis,” Seminars in oncology,
  36. (2008). Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours,”
  37. (2006). Sunitinib in patients with metastatic renal cell carcinoma,”
  38. (2010). Tabernero et al., “Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial,”
  39. (2006). The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review,”
  40. (2009). Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: Synergy or antagonism?”
  41. (2004). Zalcberg et al., “Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial,”